The FDA granted approval in early May for gefitinib (Iressa) as a treatment of last resort for lung cancer patients who had failed two or more types of chemotherapy, despite findings that treatment with a combination of gefitinib and standard platinum-based chemotherapy failed to improve survival for newly diagnosed patients. The new drug may be best suited as a chemopreventive or as maintenance therapy after upfront chemotherapy, according to oncology pharmacy experts.
Go to Previous Page
Go to Next Page